Tracking tumor-specific CD8+ T cell responses

Kelly P Burke; Samuel C Markson; Arlene H Sharpe

doi:10.1016/j.it.2023.03.012

Tracking tumor-specific CD8⁺ T cell responses

Trends Immunol. 2023 May;44(5):326-328. doi: 10.1016/j.it.2023.03.012. Epub 2023 Apr 7.

Authors

Kelly P Burke¹, Samuel C Markson², Arlene H Sharpe³

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
² Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
³ Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Evergrande Center for Immunological Diseases, Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA. Electronic address: [email protected].

Abstract

In a recent article, Puig-Saus et al. computationally predict and experimentally validate neoantigen-specific T cell responses in patients with melanoma. They identify a restricted set of neoantigens recognized by polyclonal CD8⁺ T cells as a unique feature of anti-PD-1 responders and engineer autologous tumor-responsive T cells expressing neoantigen-specific TCRs, providing proof-of-concept for future cellular therapies.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Antigens, Neoplasm
CD8-Positive T-Lymphocytes*
Humans
Melanoma* / therapy
Receptors, Antigen, T-Cell

Substances

Antigens, Neoplasm
Receptors, Antigen, T-Cell

Abstract

Publication types

MeSH terms

Substances

Grants and funding